[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurogene Inc (NGNE)

Neurogene Inc (NGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 773,025
  • Shares Outstanding, K 20,011
  • Annual Sales, $ 0 K
  • Annual Income, $ -90,350 K
  • EBIT $ -121 M
  • EBITDA $ -123 M
  • 60-Month Beta 1.70
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.76

Options Overview Details

View History
  • Implied Volatility 86.12% (-4.48%)
  • Historical Volatility 52.01%
  • IV Percentile 1%
  • IV Rank 0.85%
  • IV High 248.71% on 02/13/26
  • IV Low 84.73% on 08/19/26
  • Expected Move (DTE 27) 2.72 (7.04%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 82
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 3,002
  • Open Int (30-Day) 2,288
  • Expected Range 35.91 to 41.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.39
  • Number of Estimates 5
  • High Estimate $-1.06
  • Low Estimate $-1.69
  • Prior Year $-0.99
  • Growth Rate Est. (year over year) -40.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.57 +26.37%
on 08/11/26
40.15 -3.80%
on 08/19/26
+1.95 (+5.32%)
since 07/21/26
3-Month
24.91 +55.08%
on 06/09/26
43.66 -11.52%
on 07/09/26
+11.02 (+39.91%)
since 05/21/26
52-Week
15.93 +142.50%
on 02/05/26
43.66 -11.52%
on 07/09/26
+18.88 (+95.59%)
since 08/21/25

Most Recent Stories

More News
Neurogene: Q2 Earnings Snapshot

Neurogene: Q2 Earnings Snapshot

NGNE : 38.63 (+1.68%)
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant; no...

NGNE : 38.63 (+1.68%)
Neurogene's Gene Therapy Data May Finally Give the Market Something to Price In

Barchart Research What to Expect from NGNE Earnings NGNE Generated August 7, 2026 Current Price $35.69 EPS Estimate $$-1.39 Consensus Rating Strong Buy Average Move 9.71% Neurogene's Gene Therapy Data...

NGNE : 38.63 (+1.68%)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 38.63 (+1.68%)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 38.63 (+1.68%)
Neurogene Inc. Announces Pricing of $125 Million Public Offering

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the pricing of...

NGNE : 38.63 (+1.68%)
Neurogene Inc. Announces Proposed Public Offering

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced...

NGNE : 38.63 (+1.68%)
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

4 7 total developmental milestones gained across 10 participants, with durable treatment effect and no plateau or milestone loss through 30 months of follow-up ...

NGNE : 38.63 (+1.68%)
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community NGN-401 has been generally...

NGNE : 38.63 (+1.68%)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 38.63 (+1.68%)

Business Summary

Neurogene Inc. is a clinical-stage company which bring life-changing genetic medicines to patients and families affected by rare neurological diseases. Neurogene Inc., formerly known as Neoleukin Therapeutics Inc., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 41.44
2nd Resistance Point 40.44
1st Resistance Point 39.53
Last Price 38.63
1st Support Level 37.63
2nd Support Level 36.63
3rd Support Level 35.73

See More

52-Week High 43.66
Last Price 38.63
Fibonacci 61.8% 33.07
Fibonacci 50% 29.80
Fibonacci 38.2% 26.52
52-Week Low 15.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.